(Q37756975)

22 August 2017

1 reference

title

Pharmacotherapy of myelodysplastic syndromes (English)

1 reference

22 August 2017

0 references

Naomi Galili

1

1 reference

22 August 2017

Azra Raza

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

11

1 reference

22 August 2017

page(s)

1889-1899

1 reference

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

A comparative clinical trial of 5-azacytidine and guanazole in previously treated adults with acute nonlymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Immunomodulatory drugs in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Epigenetic modifiers: basic understanding and clinical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Remicade as TNF suppressor in patients with myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2010.485613

10.1517/14656566.2010.485613

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference